At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 935 enrolled
Drug / intervention
Nitazoxanide +2 moredrug
Likely dose
Nitazoxanide 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3, Randomized, Double-Blind, Placebo-Controlled, Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
In Brief
A Phase 3 clinical trial evaluating Nitazoxanide, Placebo, and 1 other intervention for COVID-19. Completed, enrolled 935 participants across 2 sites.
Detailed Summary
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartAug 2020
Primary CompletionFeb 2021
TodayJul 2026
First PostedJul 24, 2020
Enrollment StartAug 13, 2020
Primary CompletionFeb 8, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.9 years ago
Interventions
Nitazoxanidedrug
Two nitazoxanide 300 mg tablets administered orally twice daily with food for 5 days
Placebodrug
Two placebo tablets administered orally twice daily with food for 5 days
Vitamin Super B-Complexdietary
Vitamin Super B-Complex administered orally twice daily to maintain the blind